Systemic mastocytosis: classification, pathogenesis, diagnosis, and treatment

Area of Science:

• Hematology
• Oncology
• Dermatology

Background:

• Mastocytosis is a rare disorder characterized by abnormal mast cell accumulation.
• It presents as cutaneous mastocytosis (CM) or systemic mastocytosis (SM).
• Pediatric CM typically resolves, whereas adult CM often progresses to SM.

Observation:

• Mast cell proliferation is regulated by the c-kit receptor tyrosine kinase and its ligand, stem cell factor.
• A common finding in systemic mastocytosis is a gain-of-function mutation in c-kit at codon 816.
• Diagnostic tools include skin examination, biopsy, serum tryptase levels, and bone marrow analysis.

Findings:

• The c-kit pathway is crucial for mast cell development.
• Specific c-kit mutations are strongly associated with systemic mastocytosis.
• Current treatments involve trigger avoidance, symptom management, and cytoreductive therapies for aggressive forms.

Implications:

• Understanding the c-kit pathway opens avenues for targeted therapies.
• Development of specific c-kit tyrosine kinase inhibitors offers new treatment strategies.
• Early diagnosis and risk stratification are essential for effective management of mastocytosis.